# General

## Title

AIDS Drug Assistance Program (ADAP): percentage of identified inappropriate antiretroviral (ARV) regimen components prescriptions that are resolved by the ADAP program during the measurement year.

## Source(s)

Health Resources and Services Administration (HRSA). HAB HIV performance measures. ADAP: AIDS Drug Assistance Program. Rockville (MD): Health Resources and Services Administration (HRSA); 2009 Dec 10. 9 p.

# Measure Domain

## Primary Measure Domain

Population Health Quality Measures: Population Structure

## Secondary Measure Domain

Does not apply to this measure

# Brief Abstract

## Description

This measure is used to assess the percentage of identified inappropriate antiretroviral (ARV) regimen components prescriptions that are resolved by the AIDS Drug Assistance Program (ADAP) program during the measurement year.

## Rationale

Human immunodeficiency virus (HIV)-related morbidity and mortality has dropped dramatically due to advances in HIV/acquired immune deficiency syndrome (AIDS) treatment. But reductions are uneven across HIV-infected populations due to unequal access to care and variable quality of services provided. Quality management seeks to enhance the quality of HIV care provided and increase access to services. They do so by measuring how health and social services meet established professional standards and user expectations.

The U.S. Public Health Service (PHS) *Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents* and the *Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection* specify antiretroviral regimens or components are not generally recommended because of suboptimal antiviral potency, unacceptable toxicities, or pharmacologic concerns (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2009; Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, 2009). AIDS Drug Assistance Program (ADAP) programs are included as core medical services funded by the Ryan White HIV/AIDS Program, and are therefore, required to provide care and treatment consistent with PHS guidelines.

PHS Guidelines

Adult and Adolescents Patients: Antiretroviral Regimens or Components That Should Not Be Offered At Any Time (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2009)

| Components not recommended | Exceptions |
| --- | --- |
| Atazanavir + indinavir | No exception |
| Didanosine + stavudine | When no other antiretroviral options are available and potential benefits outweigh the risks |
| 2-non-nucleoside reverse-transcriptase inhibitor (NNRTI) combination | No exception |
| Efavirenz in first trimester of pregnancy or in women with significant child-bearing potential | When no other antiretroviral options are available and potential benefits outweigh the risks |
| Emtricitabine + lamivudine | No exception |
| Etravirine + Unboosted protease inhibitor (PI) | No exception |
| Etravirine + ritonavir-boosted atazanavir or fosamprenavir | No exception |
| Etravirine + ritonavir-boosted tipranavir | No exception |
| Nevirapine in treament-naïve women with CD4 greater than 250 or men with CD4 greater than 400 | If no other antiretroviral option available; if used patients should be closely monitored |
| Stavudine + zidovudine | No exception |
| Unboosted darunavir, saquinavir, or tipranavir | No exception |

Pediatric Patients: Antiretroviral Components Not Recommended as Part of an Antiretroviral Regimen (Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, 2009)

| Components not recommended | Exceptions |
| --- | --- |
| Atazanavir + indinavir | No exception |
| Dual nucleoside reverse transcriptase inhibitor (NRTI) combinations:<br><br>    Lamivudine + Emtricitabine<br>    Stavudine + Zidovudine<br>    Stavudine + Didanosine | No exception<br>No exception<br>May be considered for use in antiretroviral-eperienced children who require therapy change |
| Efavirenz in first trimester of pregnancy or sexually active adolescent girls of childbearing potential | When no other antiretroviral options are available and potential benefits |

| Components not recommended | outweigh risks Exceptions |
|---|---|
| Nevirapine initiation in adolescent girls with CD4 greater than 250 cells/mm or adolescent boys with CD4 greater than 400 cells/mm3 | Only if benefit clearly outweighs the risk |
| Unboosted saquinavir | No exceptions |

## Evidence for Rationale

Health Resources and Services Administration (HRSA). Deliver HIV/AIDS care: quality of care. [internet]. Rockville (MD): Health Resources and Services Administration (HRSA); [accessed 2016 Jun 23].

Health Resources and Services Administration (HRSA). HAB HIV performance measures. ADAP: AIDS Drug Assistance Program. Rockville (MD): Health Resources and Services Administration (HRSA); 2009 Dec 10. 9 p.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda (MD): Department of Health and Human Services (DHHS); 2009 Dec 1. 161 p.

Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda (MD): Department of Health and Human Services (DHHS); 2009 Feb 23. various p.

## Primary Health Components

Human immunodeficiency virus (HIV); AIDS Drug Assistance Program (ADAP); antiretroviral regimens

## Denominator Description

Number of inappropriate antiretroviral (ARV) regimen components prescriptions included in the U.S. Public Health Service guidelines, *Antiretroviral Regimens or Components That Should Not Be Offered At Any Time* and *Antiretroviral Regimens or Components That Should Not Be Offered for Treatment of Human Immunodeficiency Virus (HIV) Infection in Children* that are identified by the AIDS Drug Assistance Program (ADAP) (see the related "Denominator Inclusions/Exclusions" field)

## Numerator Description

Number of antiretroviral (ARV) regimen components prescriptions included in the U.S. Public Health Service guidelines, *Antiretroviral Regimens or Components That Should Not Be Offered At Any Time* and *Antiretroviral Regimens or Components That Should Not Be Offered for Treatment of Human Immunodeficiency Virus (HIV) Infection in Children* that are resolved by the AIDS Drug Assistance Program (ADAP) program during the measurement year

# Evidence Supporting the Measure

## Type of Evidence Supporting the Criterion of Quality for the Measure

A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

## Additional Information Supporting Need for the Measure

Unspecified

## Extent of Measure Testing

Unspecified

# State of Use of the Measure

## State of Use

Current routine use

## Current Use

not defined yet

# Application of the Measure in its Current Use

## Measurement Setting

State/Provincial Public Health Programs

## Professionals Involved in Delivery of Health Services

not defined yet

## Least Aggregated Level of Services Delivery Addressed

State/Provincial

## Statement of Acceptable Minimum Sample Size

Does not apply to this measure

## Target Population Age

Does not apply to this measure

## Target Population Gender

Does not apply to this measure

# National Framework for Public Health Quality

## Public Health Aims for Quality

Effective

Population-centered

Proactive

# National Strategy for Quality Improvement in Health Care

## National Quality Strategy Aim

Healthy People/Healthy Communities

## National Quality Strategy Priority

# Institute of Medicine (IOM) National Health Care Quality Report Categories

## IOM Care Need

Not within an IOM Care Need

## IOM Domain

Not within an IOM Domain

# Data Collection for the Measure

## Case Finding Period

The measurement year

## Denominator Sampling Frame

Clinical information

## Denominator (Index) Event or Characteristic

Does not apply to this measure

## Denominator Time Window

not defined yet

## Denominator Inclusions/Exclusions

Inclusions
Number of inappropriate antiretroviral (ARV) regimen components prescriptions included in the U.S. Public Health Service guidelines, *Antiretroviral Regimens or Components That Should Not Be Offered At Any Time* and *Antiretroviral Regimens or Components That Should Not Be Offered for Treatment of Human Immunodeficiency Virus (HIV) Infection in Children* that are identified by the AIDS Drug Assistance Program (ADAP)

Note: Refer to the original measure documentation for additional data elements.

Exclusions
For ADAP clients with multiple sources of funding for their medications, the ADAP program is responsible for identifying only ARV regimen components funded by ADAP.

## Exclusions/Exceptions

not defined yet

## Numerator Inclusions/Exclusions

Inclusions
Number of antiretroviral (ARV) regimen components prescriptions included in the U.S. Public Health Service guidelines, *Antiretroviral Regimens or Components That Should Not Be Offered At Any Time* and *Antiretroviral Regimens or Components That Should Not Be Offered for Treatment of Human Immunodeficiency Virus (HIV) Infection in Children* that are resolved by the AIDS Drug Assistance Program (ADAP) program during the measurement year

Exclusions
Unspecified

## Numerator Search Strategy

Fixed time period or point in time

## Data Source

National public health data

State/Province public health data

## Type of Health State

Does not apply to this measure

## Instruments Used and/or Associated with the Measure

Unspecified

# Computation of the Measure

## Measure Specifies Disaggregation

Does not apply to this measure

## Scoring

Rate/Proportion

## Interpretation of Score

Desired value is a higher score

## Allowance for Patient or Population Factors

not defined yet

## Standard of Comparison

not defined yet

# Identifying Information

## Original Title

ADAP: inappropriate antiretroviral regimen components resolved by ADAP.

## Measure Collection Name

HIV/AIDS Bureau (HAB) Performance Measures

## Measure Set Name

AIDS Drug Assistance Program

## Submitter

Health Resources and Services Administration - Federal Government Agency [U.S.]

## Developer

Health Resources and Services Administration - Federal Government Agency [U.S.]

## Funding Source(s)

Unspecified

## Composition of the Group that Developed the Measure

Unspecified

## Financial Disclosures/Other Potential Conflicts of Interest

Unspecified

## Adaptation

This measure was not adapted from another source.

## Date of Most Current Version in NQMC

2009 Dec

## Measure Maintenance

Unspecified

## Date of Next Anticipated Revision

Unspecified

## Measure Status

This is the current release of the measure.

## Measure Availability

Source available from the Health Resources and Services Administration (HRSA) Web site
.

For more information, contact the HRSA HIV/AIDS Bureau (HAB) at 5600 Fishers Lane, Rockville, MD
20857; E-mail: HIVmeasures@hrsa.gov; Web site: www.hrsa.gov/index.html .

## NQMC Status

This NQMC summary was completed by ECRI Institute on July 8, 2016.

## Copyright Statement

No copyright restrictions apply.

# Production

## Source(s)

# Disclaimer

## NQMC Disclaimer

The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.